JHL Biotech ropes in new CFO
Taiwan based JHL Biotech recently announced the appointment of Ellis Chu as its Chief Financial Officer (CFO). Chu most recently served as a Managing Director and the Head of Greater China at Ion Pacific, an Asiafocused venture capital merchant bank. Prior to Ion Pacific, he spent the bulk of his career in investment banking, including serving as Head of China Mergers & Acquisitions at Bank of America Merrill Lynch.
He also held senior investment banking positions at Citigroup, Nomura and Lehman Brothers advising on transactions across multiple sectors, including healthcare. Chu holds a B.S. in Electrical Engineering from Northwestern University and an MBA from Columbia Business School.
At the same time, JHL Biotech has raised $106 million in a convertible bond issuance. Proceeds raised from the issuance will be used for clinical trials, working capital needs and further development of the company’s pipeline of biosimilar treatments.